Predicting chronic postsurgical pain: current evidence and a novel program to develop predictive biomarker signatures

Kathleen A. Sluka, Tor D. Wager, Stephani P. Sutherland, Patricia A. Labosky, Tessa Balach, Emine O. Bayman, Giovanni Berardi, Chad M. Brummett, John W. Burns, Asokumar Buvanendran, Brian Caffo, Vince D. Calhoun, Daniel J. Clauw, Andrew C. Chang, Christopher S. Coffey, Dana L. Dailey, Dixie Ecklund, Oliver Fiehn, Kathleen M. Fisch, Laura Frey‐Law, Richard E. Harris, Steven E. Harte, Timothy D. Howard, Joshua Jacobs, Jon Jacobs, Kristen Jepsen, Nicolas Johnston, Carl D. Langefeld, Louise C. Laurent, Rebecca N. Lenzi, Martin A. Lindquist, Anna Lokshin, Ari E. Kahn, Robert J. McCarthy, Michael Olivier, Linda Porter, Weijun Qian, Cheryse A. Sankar, John S. Satterlee, Adam Swensen, Carol Vance, Jennifer F. Waljee, Laura D. Wandner, David A. Williams, Richard L. Wixson, Xiaohong Joe ZhouPain 2023 · DOI

TL;DR

The NIH-funded Acute to Chronic Pain Signatures (A2CPS) program is a massive, multi-modal effort to identify "biosignatures"—combinations of biological, imaging, and psychological markers—that predict which patients will develop chronic pain after surgery. By prospectively tracking thousands of patients, the project aims to move pain management from subjective self-reporting toward objective, precision-medicine-based diagnostics.

What Problem Does This Paper Address?

Chronic pain affects over 50 million Americans and costs the economy upwards of $560 billion annually. Despite its prevalence, we lack a fundamental understanding of chronification—the process by which acute pain (like that following surgery) transitions into a persistent, debilitating condition.

Currently, pain diagnosis relies almost entirely on subjective self-reporting. There are no validated clinical biomarkers to tell a surgeon which patient is at high risk for long-term suffering. This paper introduces the A2CPS program, which treats surgery as a "controlled injury" model. By measuring patients before and after surgery, researchers can finally isolate the biological and psychological "signatures" that distinguish those who recover from those who develop chronic postsurgical pain (CPSP).

Methods

A2CPS utilizes a "team science" consortium approach, integrating data across several high-tech domains to create a composite biosignature. Key methodologies include:

  • Multi-Omics: Analyzing genetic variants (SNPs), extracellular RNA (exRNA), proteomics (inflammatory cytokines), lipidomics, and metabolomics from blood samples.
  • Neuroimaging: Using structural MRI (sMRI), diffusion MRI (dMRI) for connectivity, and functional MRI (fMRI) to map brain circuits associated with pain processing and modulation.
  • Quantitative Sensory Testing (QST): Objective measures of the nervous system's sensitivity, such as pressure pain thresholds and "temporal summation" (how the brain ramps up pain signals).
  • Psychosocial Profiling: Validated patient-reported outcomes (PROs) covering anxiety, depression, catastrophizing, and resilience.
  • Predictive Modeling: The program uses a "stacked" hierarchical modeling approach. They train algorithms on a "discovery set" (66% of the data) and validate them on a "holdout set" (33%) to ensure the predictive signatures are robust and not just noise.

Datasets

The program is building a massive, prospective dataset:

  • Primary Cohorts: 1,400 patients undergoing Total Knee Arthroplasty (KA) and 1,400 patients undergoing Thoracic Surgery. These two groups allow researchers to study pain chronification in patients with pre-existing pain (KA) versus those generally without it (Thoracic).
  • Comparative Data: The study references and builds upon findings from the UK Biobank, OPPERA (Orofacial Pain), and MAPP (Urologic Pain) studies.
  • Open Science: Following FAIR principles (Findable, Accessible, Interoperable, and Reusable), the resulting dataset will be shared with the broader scientific community after the initial study goals are met.

Key Insights and Ideas

  • Pain as a Disease, Not Just a Symptom: The authors argue that chronic pain involves distinct pathophysiological changes in the central nervous system, making it a disease in its own right.
  • The Power of "Biosignatures": A single marker (like one gene or one brain region) is unlikely to predict chronic pain. The "aha moment" here is the shift toward multimodal integration—combining biological "omics" with psychological and sensory data to achieve high predictive power.
  • Resilience is Measurable: The study isn't just looking for "broken" systems; it’s actively seeking biomarkers of resilience—the biological factors that allow some patients to recover quickly despite a major surgical insult.
  • Pre-Surgical Prediction: One of the most striking insights is that the brain's "wiring" (e.g., corticostriatal connectivity) before surgery may already predispose an individual to chronic pain, suggesting that the "die is cast" earlier than we thought.

Key Results

While the A2CPS study is currently in the recruitment phase (enrollment through 2025), the paper highlights foundational evidence justifying the program:

  • Preoperative Pain: In knee arthroplasty, patients with severe movement-evoked pain before surgery have a 10-fold greater likelihood of moderate-to-severe pain six months later.
  • Psychosocial Impact: Factors like pain catastrophizing and depression show consistently high effect sizes in predicting poor surgical outcomes.
  • Brain Signatures: Previous smaller studies have shown that white matter integrity and hippocampal functional connectivity can predict back pain chronification with significant accuracy.

Limitations and Future Work

  • Cost vs. Depth: Due to budget constraints, the study opted for targeted gene sets and small RNA sequencing rather than full-genome sequencing (GWAS) for the entire cohort.
  • Participant Burden: The protocol is intensive, requiring imaging, blood draws, and sensory testing, which may impact recruitment and retention.
  • Clinical Translation: Once biosignatures are identified, the next challenge is "scaling down"—creating a cost-effective version of these tests that a local hospital can actually use.
  • Future Interventions: The ultimate goal is to use these signatures to trigger early interventions, such as "pre-habilitation" (e.g., Cognitive Behavioral Therapy or specific pharmacological protocols) for high-risk patients before they ever go under the knife.

Summary updated

Abstract

Chronic pain affects more than 50 million Americans. Treatments remain inadequate, in large part, because the pathophysiological mechanisms underlying the development of chronic pain remain poorly understood. Pain biomarkers could potentially identify and measure biological pathways and phenotypical expressions that are altered by pain, provide insight into biological treatment targets, and help identify at-risk patients who might benefit from early intervention. Biomarkers are used to diagnose, track, and treat other diseases, but no validated clinical biomarkers exist yet for chronic pain. To address this problem, the National Institutes of Health Common Fund launched the Acute to Chronic Pain Signatures (A2CPS) program to evaluate candidate biomarkers, develop them into biosignatures, and discover novel biomarkers for chronification of pain after surgery. This article discusses candidate biomarkers identified by A2CPS for evaluation, including genomic, proteomic, metabolomic, lipidomic, neuroimaging, psychophysical, psychological, and behavioral measures. Acute to Chronic Pain Signatures will provide the most comprehensive investigation of biomarkers for the transition to chronic postsurgical pain undertaken to date. Data and analytic resources generatedby A2CPS will be shared with the scientific community in hopes that other investigators will extract valuable insights beyond A2CPS's initial findings. This article will review the identified biomarkers and rationale for including them, the current state of the science on biomarkers of the transition from acute to chronic pain, gaps in the literature, and how A2CPS will address these gaps.
BibTeX
@inproceedings{sluka2023predicting,
  author = {Kathleen A. Sluka and Tor D. Wager and Stephani P. Sutherland and Patricia A. Labosky and Tessa Balach and Emine O. Bayman and Giovanni Berardi and Chad M. Brummett and John W. Burns and Asokumar Buvanendran and Brian Caffo and Vince D. Calhoun and Daniel J. Clauw and Andrew C. Chang and Christopher S. Coffey and Dana L. Dailey and Dixie Ecklund and Oliver Fiehn and Kathleen M. Fisch and Laura Frey‐Law and Richard E. Harris and Steven E. Harte and Timothy D. Howard and Joshua Jacobs and Jon Jacobs and Kristen Jepsen and Nicolas Johnston and Carl D. Langefeld and Louise C. Laurent and Rebecca N. Lenzi and Martin A. Lindquist and Anna Lokshin and Ari E. Kahn and Robert J. McCarthy and Michael Olivier and Linda Porter and Weijun Qian and Cheryse A. Sankar and John S. Satterlee and Adam Swensen and Carol Vance and Jennifer F. Waljee and Laura D. Wandner and David A. Williams and Richard L. Wixson and Xiaohong Joe Zhou},
  title = {{Predicting chronic postsurgical pain: current evidence and a novel program to develop predictive biomarker signatures}},
  booktitle = {Pain},
  year = {2023},
  doi = {10.1097/j.pain.0000000000002938},
}
Figure